Evaluation and timing optimization of CT perfusion first pass analysis in comparison to maximum slope model in pancreatic adenocarcinoma.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
30 06 2023
Historique:
received: 15 12 2022
accepted: 21 06 2023
medline: 3 7 2023
pubmed: 1 7 2023
entrez: 30 6 2023
Statut: epublish

Résumé

For implementation, performance evaluation and timing optimization of CT perfusion first pass analysis (FPA) by correlation with maximum slope model (MSM) in pancreatic adenocarcinoma, dynamic CT perfusion acquisitions of 34 time-points were performed in 16 pancreatic adenocarcinoma patients. Regions of interest were marked in both parenchyma and carcinoma. FPA, a low radiation exposure CT perfusion technique, was implemented. Blood flow (BF) perfusion maps were calculated using FPA and MSM. Pearson's correlation between FPA and MSM was calculated at each evaluated time-point to determine optimum timing for FPA. Differences in BF between parenchyma and carcinoma were calculated. Average BF for MSM was 106.8 ± 41.5 ml/100 ml/min in parenchyma and 42.0 ± 24.8 ml/100 ml/min in carcinoma, respectively. For FPA, values ranged from 85.6 ± 37.5 ml/100 ml/min to 117.7 ± 44.5 ml/100 ml/min in parenchyma and from 27.3 ± 18.8 ml/100 ml/min to 39.5 ± 26.6 ml/100 ml/min in carcinoma, depending on acquisition timing. A significant difference (p value < 0.0001) between carcinoma and parenchyma was observed at all acquisition times based on FPA measurements. FPA shows high correlation with MSM (r > 0.90) and 94% reduction in the radiation dose compared to MSM. CT perfusion FPA, where the first scan is obtained after the arterial input function exceeds a threshold of 120 HU, followed by a second scan after 15.5-20.0 s, could be used as a potential imaging biomarker with low radiation exposure for diagnosing and evaluating pancreatic carcinoma in clinical practice, showing high correlation with MSM and the ability to differentiate between parenchyma and carcinoma.

Identifiants

pubmed: 37391443
doi: 10.1038/s41598-023-37381-w
pii: 10.1038/s41598-023-37381-w
pmc: PMC10313720
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

10595

Informations de copyright

© 2023. The Author(s).

Références

PLoS One. 2013 Nov 26;8(11):e80468
pubmed: 24303017
Abdom Imaging. 2009 Nov;34(6):759-66
pubmed: 19672566
Br J Radiol. 2018 May;91(1085):20170351
pubmed: 29446319
Cancer Imaging. 2021 Jan 19;21(1):13
pubmed: 33468259
Br J Radiol. 2015 Feb;88(1046):20140683
pubmed: 25465353
Sci Rep. 2022 Jul 23;12(1):12608
pubmed: 35871187
J Comput Assist Tomogr. 2000 May-Jun;24(3):400-6
pubmed: 10864075
Circ Cardiovasc Imaging. 2016 Dec;9(12):
pubmed: 27956409
Br J Radiol. 2003;76 Spec No 1:S36-42
pubmed: 15456712
Eur Radiol. 2009 Nov;19(11):2641-6
pubmed: 19471941
Eur Radiol Exp. 2019 Apr 3;3(1):16
pubmed: 30945100
Br J Radiol. 1995 May;68(809):471-5
pubmed: 7788231
AJR Am J Roentgenol. 2016 Mar;206(3):526-35
pubmed: 26901008
Pancreatology. 2016 Nov - Dec;16(6):979-987
pubmed: 27568845
Rofo. 2021 Sep;193(9):1062-1073
pubmed: 33772484
Abdom Imaging. 1999 Nov-Dec;24(6):597-603
pubmed: 10525816
Int J Cardiovasc Imaging. 2015 Oct;31(7):1451-9
pubmed: 26156231
Invest Radiol. 2015 Oct;50(10):703-8
pubmed: 26039774
PLoS One. 2020 Feb 12;15(2):e0228110
pubmed: 32049969
Acta Radiol. 2019 Sep;60(9):1065-1073
pubmed: 30428264
Invest Radiol. 2019 Dec;54(12):774-780
pubmed: 31633574
Radiology. 2005 Dec;237(3):945-51
pubmed: 16237140
Radiology. 2018 Jan;286(1):93-102
pubmed: 29059038
Abdom Radiol (NY). 2019 Feb;44(2):593-603
pubmed: 30225610

Auteurs

Neha Vats (N)

Clinic for Diagnostic and Interventional Radiology (DIR), Heidelberg University Hospital, Im Neuenheimer Feld 130.3, 69120, Heidelberg, Germany.

Philipp Mayer (P)

Clinic for Diagnostic and Interventional Radiology (DIR), Heidelberg University Hospital, Im Neuenheimer Feld 130.3, 69120, Heidelberg, Germany.

Franziska Kortes (F)

Clinic for Diagnostic and Interventional Radiology (DIR), Heidelberg University Hospital, Im Neuenheimer Feld 130.3, 69120, Heidelberg, Germany.
Radiology Rhein-Neckar, Bodelschwinghstraße 10, 68723, Schwetzingen, Germany.

Miriam Klauß (M)

Clinic for Diagnostic and Interventional Radiology (DIR), Heidelberg University Hospital, Im Neuenheimer Feld 130.3, 69120, Heidelberg, Germany.

Lars Grenacher (L)

Clinic for Diagnostic and Interventional Radiology (DIR), Heidelberg University Hospital, Im Neuenheimer Feld 130.3, 69120, Heidelberg, Germany.
Conradia Radiology and Medical Prevention, Conradia Radiologie München, Augustenstraße 115, 80798, Munich, Germany.

Wolfram Stiller (W)

Clinic for Diagnostic and Interventional Radiology (DIR), Heidelberg University Hospital, Im Neuenheimer Feld 130.3, 69120, Heidelberg, Germany.

Hans-Ulrich Kauczor (HU)

Clinic for Diagnostic and Interventional Radiology (DIR), Heidelberg University Hospital, Im Neuenheimer Feld 130.3, 69120, Heidelberg, Germany.

Stephan Skornitzke (S)

Clinic for Diagnostic and Interventional Radiology (DIR), Heidelberg University Hospital, Im Neuenheimer Feld 130.3, 69120, Heidelberg, Germany. stephan.skornitzke@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH